Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7052W HIGH $2.59
Volume
18.86 K
Value Traded
359.41 K
Short % Float
1.55%
-15.82%Week
-33.33%1 Month
+43%3 Month
+34.98%6 Month
-89.32%5 Year
-89.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
59.12 M
EPS (TTM)
-0.27
P/E Ratio
-
Ent. Value
50.54 M
Total Shares
45.09 M
Float Shares
43.48 M
Insiders
3.66%
Institutions
20.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RNXT Catalyst Timeline
Dated clinical, regulatory and corporate events for RenovoRx, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for RenovoRx, Inc.
236Total events
21Upcoming
34Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment MilestoneTrial
First patient enrolled in investigator-initiated PRISM-TAMP trial of TAMP-delivered gemcitabine in borderline resectable PDAC
borderline resectable pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Enrollment UpdateTrial
Second patient progressing toward TAMP treatment one week after PRISM-TAMP began
borderline resectable pancreatic ductal adenocarcinoma (PDAC)source ↗
▲PublicationPresentation
Peer-reviewed case series published in Case Reports in Oncology on TAMP-mediated intra-arterial gemcitabine delivery
locally advanced pancreatic cancersource ↗
▲Trial InitiationTrial
PRISM-TAMP investigator-initiated trial began, with second patient progressing toward TAMP treatment one week later
borderline resectable pancreatic ductal adenocarcinoma (PDAC)source ↗
▲PublicationPresentation
Publication of PK/PD data from TIGeR-PaC sub-study in Cancer Chemotherapy and Pharmacology
locally advanced pancreatic cancersource ↗
▲Patent GrantedRenovoCathFiledIP / Competition
USPTO issues Notice of Allowance for patent application 18/184,620 covering RenovoCath
▲Enrollment CompleteIAGTrial
Anticipates full enrollment in TIGeR-PaC trial in very near term
pancreatic cancersource ↗
▲Enrollment CompleteIAGTrial
Full enrollment achieved in Phase III TIGeR-PaC trial
locally advanced pancreatic cancersource ↗
▲Enrollment CompleteRenovoCathFiledTrial
Phase III TIGeR-PaC trial reaches full enrollment
locally advanced pancreatic cancersource ↗
▲Product LaunchRenovoCathFiledPost-Market
First commercial clinical use of RenovoCath in sarcoma
sarcomasource ↗
▲Enrollment CompleteIAGTrial
Full enrollment achieved in Phase III TIGeR-PaC trial of intra-arterial gemcitabine
pancreatic cancersource ↗
▲PK PD DataIAGClinical Data
PK-PD data from TIGeR-PaC sub-study published
locally advanced pancreatic cancersource ↗
▲PublicationIAGPresentation
PK-PD data from TIGeR-PaC sub-study published in Cancer Chemotherapy and Pharmacology
locally advanced pancreatic cancersource ↗
▲Enrollment CompleteTrial
Full enrollment achieved in Phase III TIGeR-PaC trial of IAG
pancreatic cancersource ↗
▲Enrollment CompleteIAGTrial
Full enrollment expected in TIGeR-PaC trial in very near future
locally advanced pancreatic cancersource ↗
▲Orphan Drug DesignationoxaliplatinDesignation
FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer
pancreatic cancersource ↗
◆Oral PresentationPresentation
CEO Shaun Bagai to present at iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
▲PublicationPresentation
Publication of case study on TAMP with RenovoCath for intra-arterial gemcitabine in LAPC
locally advanced pancreatic cancersource ↗
▲Orphan Drug DesignationoxaliplatinDesignation
FDA Orphan Drug Designation granted for oxaliplatin in pancreatic cancer
pancreatic cancersource ↗
▲Enrollment CompleteIAGTrial
Notification of closure of enrollment in Phase III TIGeR-PaC trial
locally advanced pancreatic cancersource ↗
▲Enrollment CompleteRenovoCathFiledTrial
Full enrollment expected in TIGeR-PaC trial
locally advanced pancreatic cancersource ↗
▲Product LaunchRenovoCathFiledPost-Market
First commercial clinical use of RenovoCath in sarcoma patient treatment
sarcomasource ↗
◆Oral PresentationIAGPresentation
PK/PD sub-study presentation at 2026 ASCO Annual Meeting
locally advanced pancreatic cancersource ↗
▲Orphan Drug DesignationoxaliplatinDesignation
FDA granted Orphan Drug Designation for oxaliplatin for pancreatic cancer
pancreatic cancersource ↗
◆AbstractIAGPresentation
PK/PD sub-study abstract accepted for presentation at 2026 ASCO Annual Meeting
locally advanced pancreatic cancersource ↗
◆Oral PresentationPresentation
RenovoRx to present at Alliance Global Partners Virtual Annual Healthcare Company Showcase
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Highlights Conference Call
◆Oral PresentationPresentation
Presentation at 2026 SIR Annual Scientific Meeting
locally advanced pancreatic cancersource ↗
▲Patent GrantedRenovoCathFiledIP / Competition
First Japanese patent allowed for RenovoCath device
◆Enrollment CompleteIAGTrial
Enrollment completion expected in first half of 2026
locally advanced pancreatic cancersource ↗
▲PublicationRenovoCathFiledPresentation
Moffitt Cancer Center case study published in Radiology Case Reports
locally advanced pancreatic cancersource ↗
●Trial InitiationTrial
New investigator-initiated trial in cholangiocarcinoma started
cholangiocarcinomasource ↗
▲Orphan Drug DesignationoxaliplatinDesignation
FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer
pancreatic cancersource ↗
▲PublicationPresentation
Case series accepted in Case Reports in Oncology
locally advanced pancreatic cancersource ↗
▲Quarterly UpdateCorporate
Record quarterly RenovoCath revenue of $909,000 in Q2 2026 and approximately $1.1 million in first full commercial year 2025
▲Quarterly UpdateRenovoCathFiledCorporate
In Q1 2026, expect at least 10 new patients to begin TAMP in a customer base of 12 centers
◆Quarterly UpdateCorporate
Q4 and Full Year 2025 Financial Results and Business Highlights Conference Call
▲Enrollment MilestoneRenovoCathFiledTrial
100th patient randomized in TIGeR-PaC trial
locally advanced pancreatic cancersource ↗
▲Enrollment MilestoneIAGTrial
TIGeR-PaC trial surpasses 100 randomized patients
locally advanced pancreatic cancersource ↗
▲Enrollment CompleteTrial
Phase III TIGeR-PaC trial enrollment nearing completion
pancreatic cancersource ↗
▲Quarterly UpdateRenovoCathFiledCorporate
12 U.S. cancer centers now utilizing RenovoCath commercially
●Management ChangeCorporate
Ramtin Agah, MD appointed to additional position of Executive Chairman
◆AbstractPresentation
Clinical data abstract accepted at 2026 SIR Annual Scientific Meeting
locally advanced pancreatic cancersource ↗
◆Poster PresentationPresentation
Clinical data on TAMP therapy platform presented at SIO 2026 Annual Scientific Meeting
solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How RNXT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-09 | RenovoCath® (intra-arterial gemcitabine) | Phase 3 PK/PD sub-study presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RNXT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| gemcitabine Orphan | locally advanced pancreatic cancer | Phase 3 | 2026-08-25 | approximately 51% drug extraction at the tumor site; significantly lower total systemic gemcitabine exposure compared to IVG; Pearson’s r = -0.75; P = 0.034Read More | RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| VOLL MARKOfficer (Chief Financial Officer) | Buy | 25,000 142,380 held | $0.79 | 05/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RNXT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RNXT for Q2 2026. | ||||
RNXT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RNXT ranks across every disease it competes in
Competitive Position is a premium feature
See how RNXT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRNXT News
RNXT▼ -1.9%today
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx has announced the enrollment of the first patient in the PRISM-TAMP trial, which evaluates the efficacy of gemcitabine delivered via the TAMP platform for borderline resectable pancreatic cancer. This investigator-initiated trial, sponsored by the University of Vermont, aims to assess tumor regression and surgical outcomes. The trial marks a significant step for RenovoRx's IIT program, focusing on localized treatment strategies.
Read more →RNXTRenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx announced a peer-reviewed publication detailing the successful use of its TAMP platform for delivering chemotherapy to patients with locally advanced pancreatic cancer. The case series highlighted significant tumor response in two patients who were previously unresponsive to standard treatments. The findings support the potential of RenovoCath in improving therapeutic delivery for challenging cancer cases.
Read more →RNXT▲ +19.4%on this news
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
RenovoRx, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Shaun Bagai and CFO Mark Voll will discuss the company's record revenue and the clinical use of their FDA-cleared device, RenovoCath. They will also provide updates on the Phase III TIGeR-PaC trial for pancreatic cancer, which is expected to complete in early 2027.
Read more →RNXT▲ +13.6%on this news· ran to +34% by day 3
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
RenovoRx announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its Phase III TIGeR-PaC trial. The study demonstrated that the TAMP platform achieved approximately 51% drug extraction at the tumor site, significantly lowering systemic exposure. Additionally, a strong correlation was found between drug metabolite levels and tumor marker reduction, suggesting improved treatment efficacy.
Read more →RNXTRenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
RenovoRx has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this by maintaining a closing bid price of $1.00 or greater for ten consecutive business days. CEO Shaun Bagai highlighted recent successes, including record revenue and the completion of enrollment in a significant clinical trial, indicating a positive outlook for future growth.
Read more →RNXTRenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
RenovoRx has received a Notice of Allowance from the USPTO for its patent application related to the RenovoCath device, enhancing its intellectual property portfolio. This patent will provide additional protection for the company's targeted drug-delivery technology, which aims to improve cancer treatment precision. The CEO emphasized the importance of this development for their commercialization strategy and ongoing clinical trials.
Read more →RNXT▲ +12.5%on this news· ran to +25% by day 1
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
RenovoRx reported record revenue of $909,000 for Q2 2026, marking a 61% increase from the previous quarter. The company has expanded the use of its RenovoCath device to treat sarcoma and achieved full enrollment in its Phase III TIGeR-PaC trial. With a positive outlook, RenovoRx raised its annual revenue guidance to between $3.75 million and $4.25 million for 2026.
Read more →RNXTRenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx has successfully completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer (LAPC). The trial aims to evaluate the efficacy of intra-arterial gemcitabine delivered via the RenovoCath device. Completion of the trial is expected in the first half of 2027, with initial data readout anticipated in the second half of 2027. This milestone reflects strong collaboration and recruitment efforts.
Read more →RNXT▲ +8.5%on this newsshared move
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
RenovoRx has announced the first commercial clinical use of its RenovoCath device for treating a sarcoma patient at CARTI Cancer Center. This marks a significant milestone as the device is also being utilized for pancreatic cancer treatment, showcasing its potential for localized drug delivery in various solid tumors. The company aims to broaden its applications and improve treatment outcomes.
Read more →RNXTRenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
RenovoRx, Inc. will participate in a JonesTrading webinar on August 13, 2026, focusing on its TAMP platform for pancreatic cancer treatment. The event will feature key opinion leaders discussing the evolving treatment landscape and the ongoing Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine. RenovoRx aims to expand its commercial presence and enhance revenue through its FDA-cleared RenovoCath device.
Read more →RNXTRenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
RenovoRx will host its second quarter 2026 financial results conference call on August 12, 2026. The call will cover the company's revenue growth from RenovoCath sales and updates on the Phase III TIGeR-PaC clinical trial for pancreatic cancer. The company has also received FDA Orphan Drug Designation for oxaliplatin.
Read more →RNXTRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
RenovoRx announced a peer-reviewed publication highlighting the successful use of its RenovoCath device for intra-arterial gemcitabine delivery in a patient with locally advanced pancreatic cancer. The case study demonstrated a significant reduction in tumor metabolic activity as observed through PET-CT imaging. The patient underwent eight treatments without complications, showcasing the potential of the TAMP procedure in optimizing cancer therapy.
Read more →RNXT▲ +7.7%on this news
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
RenovoRx announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026. The presentation will highlight the company's record Q1 2026 revenue and the accelerating adoption of its RenovoCath drug-delivery device. Additionally, Mr. Bagai will update on the Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine for pancreatic cancer. The company also received FDA Orphan Drug Designation for oxaliplatin, enhancing its oncology pipeline.
Read more →RNXT▲ +6.2%on this news
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
RenovoRx has received FDA Orphan Drug Designation for oxaliplatin, enhancing its pipeline for pancreatic cancer treatment. This marks the company's second designation for pancreatic cancer, highlighting its innovative RenovoCath device's capacity for targeted drug delivery. The designation offers regulatory advantages, including seven years of market exclusivity and financial incentives for clinical research.
Read more →RNXTRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx has announced promising pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC clinical trial, focusing on the TAMP platform for intra-arterial delivery of gemcitabine. The results indicate that this method may increase local drug potency and decrease systemic exposure, potentially leading to fewer side effects. The findings were published ahead of the ASCO Annual Meeting, highlighting a significant advancement in treatment for locally advanced pancreatic cancer. This research supports the ongoing efforts of RenovoRx to innovate within targeted oncology therapies.
Read more →RNXTRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
RenovoRx, Inc. will present at the Alliance Global Partners Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will discuss the company's commercial progress, including record revenue from its RenovoCath device and ongoing clinical trials. The Phase III TIGeR-PaC trial for a novel drug-device combination in pancreatic cancer is nearing full enrollment, with final data expected in mid to late 2027.
Read more →RNXTRenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
RenovoRx reported a record revenue of $563,000 for Q1 2026, marking a 136% increase from the previous quarter. The company expanded its active cancer center customers to 16 and anticipates continued growth supported by a robust sales pipeline. The Phase III TIGeR-PaC trial is on track for full enrollment by June 2026, which may further enhance commercial opportunities. RenovoRx ended the quarter with $12.4 million in cash, sufficient to fund operations into at least the second half of 2027.
Read more →RNXTRenovoRx Reports Record First Quarter 2026:
RenovoRx reported a record revenue of $563,000 for Q1 2026, marking a 136% increase compared to the previous quarter. The company has expanded its active commercial cancer center customers to 16 and continues to build a substantial sales pipeline, with 32 additional centers in various stages of activation. RenovoRx's Phase III TIGeR-PaC trial is on track for full enrollment by June 2026, a critical milestone for the company's dual-track strategy. Additionally, with strong cash reserves, RenovoRx is well-positioned for sustained growth in the coming quarters.
Read more →RNXTThe Most Innovative Medical Device Companies of 2026
The article highlights RenovoRx, Medtronic, Uresta, and Cionic as leading innovators in the medical device industry. It emphasizes a shift from traditional hardware-centric approaches to integrated ecosystems that utilize data, sensors, and adaptive technologies. This transformation aims to enhance the functionality and effectiveness of medical devices.
Read more →RNXTRenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
RenovoRx, Inc. will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026. The company is expected to discuss its positive sales momentum for the RenovoCath device and updates on the Phase III TIGeR-PaC trial for pancreatic cancer. The trial is nearing full enrollment, with completion anticipated in the first half of 2026.
Read more →About RenovoRx, Inc.
Headquarters2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040
BIOPHARMAWATCH ELITE PLUS
Trade the next RNXT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime